AstraZeneca resumes clinical trials in United Kingdom after green signal

Henrietta Brewer
September 13, 2020

British-based drug firm AstraZeneca says it has resumed clinical trials of a coronavirus vaccine following confirmation by British health authorities that it was safe to do so.

"On Sunday September 6 our standard review process triggered a study pause to vaccination across all of our global trials to allow the review of safety data by an independent safety review committee, and the national regulators".

"The UK committee has concluded its investigations and recommended to the Medicines Health Regulatory Authority (MHRA) that trials in the UK are safe to resume".

It comes as a big boost to the UK's most high profile vaccine trial - which previously has shown strong immune responses in volunteers.

Clinical trials of one of the most advanced experimental Covid-19 vaccines resumed on Saturday after a brief safety pause, as infection numbers continued to march upward in countries across the globe. The news was met with a range of questions from skeptics from some western countries and scientists, mainly because the vaccine had received approval before full clinical trials have been completed.


Recently, the vaccine progressed to Phase 3 testing, which meant it was able to be trialled on large numbers of patients across different geographies.

The trial of the Oxford/AstraZeneca Covid-19 vaccine has resumed after an adverse reaction in a participant.

The company said it could not disclose further medical information.

While the Chinese infrastructure workers aren't part of the company's formal clinical trials, Mr. Zhou said that the company had collected data in multiple countries showing that their vaccinations had protected them for several months.

Three COVID-19 vaccines are ahead in the race in India.


After cases of human-to-human transmissions were confirmed outside of China, the World Health Organization (WHO) declared the coronavirus outbreak an worldwide public health emergency, but due to a sharp surge in cases, it was soon forced to issue a new statement declaring the outbreak a pandemic.

Earlier in the week AstraZeneca had paused worldwide studies of its candidate vaccine after one United Kingdom participant developed symptoms consistent with the spinal cord inflammation known as transverse myelitis. Scientific voices point out that pausing clinical trials to review and redirect course, if need be, was in fact sound in science.

The vaccine produced by Moderna had shown good results in monkeys against the coronavirus and was first inducted into human trials in March this year, yielding promising results.

He then warned that using a vaccine that had yet to undergo the final trials wherein it is tested on an increased number of consenting people could destroy humanity.


Other reports by iNewsToday

FOLLOW OUR NEWSPAPER